{"organizations": [], "uuid": "99f3068b148affb08be7120137fca6f66482b810", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180413.html", "section_title": "Archive News &amp; Video for Friday, 13 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-inventiva-raises-capital-increase/brief-inventiva-raises-capital-increase-of-35-5-million-euros-idUSFWN1RP158", "country": "US", "domain_rank": 408, "title": "BRIEF-Inventiva Raises Capital Increase of 35.5 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.091, "site_type": "news", "published": "2018-04-13T14:35:00.000+03:00", "replies_count": 0, "uuid": "99f3068b148affb08be7120137fca6f66482b810"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-inventiva-raises-capital-increase/brief-inventiva-raises-capital-increase-of-35-5-million-euros-idUSFWN1RP158", "ord_in_thread": 0, "title": "BRIEF-Inventiva Raises Capital Increase of 35.5 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13 (Reuters) - Inventiva SA:\n* INVENTIVA RAISES â‚¬35.5 MILLION THROUGH A CAPITAL INCREASE WITH EUROPEAN AND US INVESTORS\n* INTENDS TO USE NET PROCEEDS FROM THIS CAPITAL INCREASE AS FOLLOWS\n* TO USE EUR 12 MILLION TO ENSURE CLINICAL DEVELOPMENT OF ODIPARCIL\n* TO USE NET PROCEEDS; EUR 3.5 MILLION TO ENSURE DEVELOPMENT OF ON-GOING DISCOVERY PROGRAMMES\n* EUR 16 MILLION TO ENSURE CLINICAL DEVELOPMENT OF LANIFIBRANOR\n* EXPECTED TO PROVIDE COMPANY WITH A CASH RUNWAY BASED ON ON-GOING PROGRAMMES TO MID-2020\n* ISSUED 5,572,500 NEW SHARES WITH A PAR VALUE OF EUR 0.01 AT A PRICE OF EUR 6.37 PER SHARE\n* AND WILL USE REMAINDER TO FINANCE OTHER CORPORATE PURPOSES\n* ISSUE PRICE OF NEW SHARES REPRESENTED A DISCOUNT OF 20% TO 3 DAY VOLUME WEIGHTED AVERAGE PRICE PRECEDING PRICING Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T14:35:00.000+03:00", "crawled": "2018-04-14T13:20:29.020+03:00", "highlightTitle": ""}